Test Price
2,800 AED✅ Home Collection Available
LMNA Gene Heart‑Hand Syndrome, Slovenian Type – Genetic Test in UAE
Executive Summary & Core Metrics
✅ Diagnostic Sensitivity >99.9% – ISO 9001:2015 Certified | Secure Home Collection Available
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity achieved via ISO‑accredited NGS processing, certified under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection by certified phlebotomists daily from 8 AM to 11 PM. Sample integrity is maintained from your doorstep to our genomics laboratory.
- Clinical Guidance: Complimentary tele‑post‑test clinical correlation session with a genetic counsellor to interpret your LMNA variant report and discuss family screening implications.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 – confirm coverage before scheduling your collection.
Test Overview & Methodology
The LMNA Gene Heart‑Hand Syndrome, Slovenian Type NGS Test utilises Next‑Generation Sequencing to analyse the entire coding region of the LMNA gene for pathogenic variants associated with dilated cardiomyopathy and brachydactyly. This definitive genetic analysis empowers cardiologists and clinical geneticists to confirm a molecular diagnosis, guide family screening, and inform personalised management plans.
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Next‑Generation Sequencing (Illumina® platform) | Single‑gene Sanger sequencing |
| Genomic Coverage | Full LMNA gene (exons + splice junctions) | Limited to targeted exons only |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Sensitivity for LMNA | >99.9% (reads all variants) | ~80% (misses deep intronic mutations) |
Physician Insight & Safety Protocols
“A definitive molecular diagnosis of LMNA‑related heart‑hand syndrome provides critical risk stratification for patients and their blood relatives. However, variant interpretation must always be integrated with the full clinical picture, including echocardiographic and electrophysiological data. I strongly advise that every genetic report be reviewed jointly by the managing cardiologist and a clinical geneticist before any therapeutic or surveillance decisions are modified.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory – Medication Continuation
⚠️ Do not discontinue any prescribed cardiac medication (beta‑blockers, ACE inhibitors, anticoagulants, or antiarrhythmics) without consulting your treating physician. Genetic results are intended to complement, not replace, your ongoing clinical management plan.
Exclusion Criteria & Safety Checklist
Important Safety Checklist – Read Before Sample Collection
- Exclusion Criteria: Active severe infection, acute myocardial infarction within 4 weeks, or any bleeding disorder (platelet count < 50,000/μL). Defer collection until resolved.
- DNA Contamination Risk: Avoid whole‑blood collection if you have received a blood transfusion within the last 3 months; please contact our coordination team to arrange an FTA card or extracted DNA alternative.
- Emergency Red Flags: If you experience chest pain, syncope, or palpitations shortly after sample collection, seek immediate medical evaluation at the nearest emergency department.
Patient FAQ & Clinical Guidance
1. What does the LMNA Heart‑Hand Syndrome test detect?
This NGS test detects single nucleotide variants, small insertions/deletions, and copy‑number changes across the entire LMNA gene that are linked to Slovenian‑type heart‑hand syndrome cardiomyopathy. It identifies both known pathogenic mutations and novel variants that may affect lamin A/C protein function, enabling precise diagnosis and risk stratification for affected families.
2. Is home collection safe and reliable for genetic samples?
Yes. Our DHA‑licensed phlebotomists use validated temperature‑controlled cold‑chain transport to maintain DNA stability, guaranteeing sample integrity comparable to hospital‑drawn specimens. The entire process is ISO‑certified, and all contact points adhere to UAE infection‑control standards.
3. How long does it take to receive results, and is a genetic counselling session included?
Results are delivered within 3 to 4 weeks from sample receipt. Your report includes a complimentary tele‑consultation with a licensed genetic counsellor who will explain the variant, its clinical implications, and the recommended cascade screening for at‑risk family members.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection: This genetic testing service strictly adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. All genetic data is stored within UAE sovereign data centres. ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | LMNA Gene Heart‑Hand Syndrome, Slovenian Type – Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina® Platform |
| ICD-10-CM Code | Q87.8, I42.8 |
| LOINC Code | 21628-4 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians